Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures

References

• BergATIdentification of pharmacoresistant epilepsyNeurol Clin20092741003101319853220
   PubMed Web of Science ®Google Scholar
• PeruccaPGilliamFGAdverse effects of antiepileptic drugsLancet Neurol201211979280222832500
   PubMed Web of Science ®Google Scholar
• LeporiniCDe SarroGRussoEAdherence to therapy and adverse drug reactions: is there a link?Expert Opin Drug Saf201413Suppl 1S41S5525171158
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKALevetiracetam: a review of its use in epilepsyDrugs201171448951421395360
   PubMed Web of Science ®Google Scholar
• Mendoza-TorreblancaJGVanoye-CarloAPhillips-FarfanBVCarmona-AparicioLGomez-LiraGSynaptic vesicle protein 2A: basic facts and role in synaptic functionEur J Neurosci201338113529353924102679
   PubMed Web of Science ®Google Scholar
• KendaBMMatagneACTalagaPEDiscovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activityJ Med Chem200447353054914736235
   PubMed Web of Science ®Google Scholar
• LynchBALambengNNockaKThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetamProc Natl Acad Sci U S A2004101269861986615210974
   PubMed Web of Science ®Google Scholar
• GillardMFuksBLeclercqKMatagneABinding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant propertiesEur J Pharmacol20116641–3364421575627
   PubMed Web of Science ®Google Scholar
• KaminskiRMMatagneALeclercqKSV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsyNeuropharmacology200854471572018207204
   PubMed Web of Science ®Google Scholar
• MatagneAMargineanuDGKendaBMichelPKlitgaardHAnti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2ABr J Pharmacol200815481662167118500360
   PubMed Web of Science ®Google Scholar
• BialerMJohannessenSILevyRHPeruccaETomsonTWhiteHSProgress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII)Epilepsy Res20151118514125769377
   PubMed Web of Science ®Google Scholar
• DetraitERLeclercqKLoscherWBrivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled ratsEpilepsy Res2010911748320678901
   PubMed Web of Science ®Google Scholar
• DupuisNMatagneAStaelensLAnti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature ratsEpilepsia201556580080525818358
   PubMed Web of Science ®Google Scholar
• WasterlainCGBaldwinRNaylorDEThompsonKWSuchomelovaLNiquetJRational polytherapy in the treatment of acute seizures and status epilepticusEpilepsia201152Suppl 8707121967369
   PubMed Web of Science ®Google Scholar
• TaiKKTruongDDBrivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonusJ Neural Transm2007114121547155117690949
   PubMed Web of Science ®Google Scholar
• NygaardHBKaufmanACSekine-KonnoTBrivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse modelAlzheimers Res Ther2015712525945128
   PubMed Web of Science ®Google Scholar
• ZonaCPieriMCarunchioICurcioLKlitgaardHMargineanuDGBrivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in cultureEpilepsy Res2010881465419914041
   PubMed Web of Science ®Google Scholar
• KohlingRVoltage-gated sodium channels in epilepsyEpilepsia200243111278129512423377
   PubMed Web of Science ®Google Scholar
• RogawskiMALoscherWThe neurobiology of antiepileptic drugsNat Rev Neurosci20045755356415208697
   PubMed Web of Science ®Google Scholar
• NiespodzianyIAndreVMLeclereNHanonEGhisdalPWolffCBrivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neuronsCNS Neurosci Ther201521324125125444522
   PubMed Web of Science ®Google Scholar
• Sargentini-MaierMLEspiePCoquetteAStockisAPharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjectsDrug Metab Dispos2008361364517908923
   PubMed Web of Science ®Google Scholar
• Sargentini-MaierMLRolanPConnellJThe pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy malesBr J Clin Pharmacol200763668068817223857
   PubMed Web of Science ®Google Scholar
• RolanPSargentini-MaierMLPigeoletEStockisAThe pharma-cokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy menBr J Clin Pharmacol2008661717518341673
   PubMed Web of Science ®Google Scholar
• Sargentini-MaierMLSokalskiABoulangerPJacobsTStockisABrivaracetam disposition in renal impairmentJ Clin Pharmacol201252121927193322235139
   PubMed Web of Science ®Google Scholar
• StockisASargentini-MaierMLHorsmansYBrivaracetam disposition in mild to severe hepatic impairmentJ Clin Pharmacol201353663364123649964
   PubMed Web of Science ®Google Scholar
• von RosenstielPBrivaracetam (UCB 34714)Neurotherapeutics200741848717199019
   PubMed Web of Science ®Google Scholar
• StockisAWatanabeSRouitsEMatsugumaKIrieSBrivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotypeDrug Metab Pharmacokinet201429539439924717838
   PubMed Web of Science ®Google Scholar
• NicolasJMChanteuxHRosaMWatanabeSStockisAEffect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjectsDrug Metab Dispos20124081466147222538270
   PubMed Web of Science ®Google Scholar
• TianXYuanMZhouQWangXThe efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studiesExpert Opin Pharmacother201516121755176726165169
   PubMed Web of Science ®Google Scholar
• FrenchJACostantiniCBrodskyAvon RosenstielPGroupNSAdjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trialNeurology201075651952520592253
   PubMed Web of Science ®Google Scholar
• Van PaesschenWHirschEJohnsonMFalterUvon RosenstielPEfficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trialEpilepsia2013541899722813235
   PubMed Web of Science ®Google Scholar
• RyvlinPWerhahnKJBlaszczykBJohnsonMELuSAdjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trialEpilepsia2014551475624256083
   PubMed Web of Science ®Google Scholar
• BitonVBerkovicSFAbou-KhalilBSperlingMRJohnsonMELuSBrivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trialEpilepsia2014551576624446953
   PubMed Web of Science ®Google Scholar
• KleinPSchiemannJSperlingMA randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with partial-onset seizures (S31.009)Neurology Available from: https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/7.Conferences/1.CONFERENCES/1.Annual_Meeting/15AM%20AbstractListing.pdfAccessed October 12, 2015
   Google Scholar
• KwanPTrinkaEVan PaesschenWRektorIJohnsonMELuSAdjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trialEpilepsia2014551384624116853
   PubMed Web of Science ®Google Scholar
• CrespelAGelissePReedRCManagement of juvenile myoclonic epilepsyEpilepsy Behav201328Suppl 1S81S8623756489
   PubMed Web of Science ®Google Scholar
• MagauddaAFerlazzoENguyenVHGentonPUnverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patientsEpilepsia200647586086616686650
   PubMed Web of Science ®Google Scholar
• FranceschettiSMichelucciRCanafogliaLProgressive myoclonic epilepsies: definitive and still undetermined causesNeurology201482540541124384641
   PubMed Web of Science ®Google Scholar
• StockisAWatanabeSFauchouxNInteraction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled studyEpilepsia2014553e27e3124512385
   PubMed Web of Science ®Google Scholar
• RosillonDAstrucBHulhovenREffect of brivaracetam on cardiac repolarisation – a thorough QT studyCurr Med Res Opin20082482327233718601811
   PubMed Web of Science ®Google Scholar
• BialerMJohannessenSILevyRHPeruccaETomsonTWhiteHSProgress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)Epilepsy Res200983114319008076
   PubMed Web of Science ®Google Scholar
• StockisAChanteuxHRosaMRolanPBrivaracetam and carbamazepine interaction in healthy subjects and in vitroEpilepsy Res2015113192725986188
   PubMed Web of Science ®Google Scholar
• MaJHuangSYouCAdjunctive brivaracetam for patients with refractory partial seizures: a meta-analysis of randomized placebo-controlled trialsEpilepsy Res2015114596526088886
   PubMed Web of Science ®Google Scholar
• MulaMSanderJWTrimbleMRThe role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: a study on levetiracetamSeizure200615640540816809055
   PubMed Web of Science ®Google Scholar
• van VlietEAAronicaERedekerSBoerKGorterJADecreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsyEpilepsia200950342243318717715
   PubMed Web of Science ®Google Scholar
• GambardellaALabateAColosimoEAmbrosioRQuattroneAMonotherapy for partial epilepsy: focus on levetiracetamNeuropsychiatr Dis Treat200841333818728811
   PubMedGoogle Scholar